Analyst maintained a Buy rating on Corcept Therapeutics on July 28, 2025.
1 report, 1 independent
Updated Jul 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst maintained a Buy rating on Corcept Therapeutics on July 28, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Corcept Therapeutics
American pharmaceutical company
Related events
- Investor activity regarding Corcept Therapeutics, including RBC boosting holdings and Amundi buying, was disclosed via SEC filings.
- Celcuity Inc. and Corcept Therapeutics are noted for developing targeted therapies in the United States.
- Corcept Therapeutics is seeking final approval from the European Commission for a cancer therapy already approved in the US market.
- Corcept Therapeutics and Twist Bioscience are noted as holdings within the First Trust biotech fund.
- Corcept Therapeutics disclosed insider trading activity via SEC filings.
Coverage
Newest first; wire copies grouped- Insider MonkeyH.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most profitable biotech stocks to invest in now. On July 14,